Welcome to our dedicated page for Tscan Therapeutics SEC filings (Ticker: TCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TScan Therapeutics’ filings can run hundreds of pages, packed with clinical data, FDA milestones, and cash-burn details that directly shape valuation. If you have ever combed a 10-K just to confirm runway or scrolled EDGAR for lab-results buried in an 8-K, you know the challenge.
Stock Titan turns that complexity into clarity. Our AI digests every submission the moment it hits EDGAR, from the TScan Therapeutics quarterly earnings report 10-Q filing to sudden 8-K trial updates. Interactive summaries point to R&D expense trends, partnership terms, and risk-factor shifts so you can focus on decisions, not document hunting.
Need real-time sentiment? Follow TScan Therapeutics insider trading Form 4 transactions as they post. Alerts surface TScan Therapeutics executive stock transactions Form 4 minutes after insiders act, helping professionals monitor confidence ahead of material events. Curious how dilution risks evolve? Our platform flags S-3 shelves, at-the-market programs, and equity offerings the second they appear.
Key resources we map for you:
- Annual insight: TScan Therapeutics annual report 10-K simplified with AI-highlighted burn-rate tables and trial timelines.
- Quarterly pulse: AI-tagged metrics in each 10-Q for faster TScan Therapeutics earnings report filing analysis.
- Material events: TScan Therapeutics 8-K material events explained—from RMAT awards to clinical holds—in plain English.
- Governance focus: TScan Therapeutics proxy statement executive compensation summarized alongside peer med-tech benchmarks.
Whether you’re understanding TScan Therapeutics SEC documents with AI for due diligence or tracking TScan Therapeutics Form 4 insider transactions real-time, Stock Titan provides the comprehensive, continuously updated view you need—TScan Therapeutics SEC filings explained simply.
Dropbox, Inc. (ticker: DBX) filed a Form 4 on 2 July 2025 reporting two open-market sales of Class A common stock by Chief Financial Officer Timothy Regan.
- Transaction dates & volumes: 2,500 shares sold on 30 Jun 2025 at $28.40; 10,000 shares sold on 1 Jul 2025 at a weighted-average $27.9392.
- Total shares sold: 12,500, representing approximately 2.4 % of the executive’s post-sale holdings.
- Remaining ownership: 516,094 Class A shares held directly.
- Trading plan: All sales executed under a Rule 10b5-1 plan adopted on 15 May 2024, indicating pre-arranged, schedule-based transactions.
- Equity mix: Remaining position includes restricted stock awards/units that vest through 15 Feb 2029; any unvested awards cancel if employment ends.
The filing discloses no derivative transactions and contains no indication of additional insider participation. While insider sales can be perceived negatively, the modest size relative to Regan’s continuing stake and the existence of a 10b5-1 plan mitigate potential signaling risk. No operational or financial performance metrics were provided in this document.
Lightwave Logic, Inc. (LWLG) Form 4 filing: Director Craig Ciesla was granted 80,645 restricted stock units (RSUs) on 06/30/2025 under the company’s 2025 Equity Incentive Plan at $0.00 exercise price. The award vests in four tranches: 20,162 RSUs on 07/15/2025 and 20,161 RSUs on each of 09/30/2025, 12/31/2025 and 03/31/2026, contingent on continued service. Following the grant, Ciesla’s total beneficial ownership equals 80,645 RSUs, all held directly. No common shares were sold or disposed of, so the filing signals no insider selling pressure. While the grant is non-cash and non-dilutive until vested and settled, the shares will add modest dilution when they convert to common stock.
GS Finance Corp. is offering $1.08 million of Autocallable Contingent Coupon Equity-Linked Notes due 2028, fully and unconditionally guaranteed by The Goldman Sachs Group, Inc. The notes are tied to the performance of Palantir Technologies Inc. (PLTR) Class A common shares and form part of Goldman’s Series F medium-term note program.
Key commercial terms
- Face amount: $1,000 per note (aggregate $1.08 million)
- Issue price: 100% (trade date 30-Jun-2025; settlement 03-Jul-2025)
- Quarterly contingent coupon: $69.625 (6.9625% per quarter, up to 27.85% p.a.) payable only if PLTR closes at or above 60% of the initial price ($136.32) on the relevant observation date.
- Automatic call: If PLTR closes at or above the initial price on any quarterly call observation date from Sep-2025 to Mar-2028, the notes are redeemed at par plus the due coupon.
- Downside protection: 40% buffer. If the final price on 30-Jun-2028 is ≥60% of the initial price, holders receive par plus any final coupon. If below 60%, repayment equals par plus (index return × par), exposing investors to full downside beyond the buffer.
- Estimated value at pricing: ~$970 per $1,000, reflecting structuring fees and dealer margin; underwriting discount 2%.
- Secondary market: GS & Co. may, but is not obliged to, make a market; bid/ask reflects estimated value plus declining premium (initially $25).
- Credit: senior unsecured obligation of GS Finance Corp. with unconditional guarantee from The Goldman Sachs Group, Inc.; not FDIC insured.
Risk highlights
- Investors may receive no coupons if PLTR trades below the 60% trigger on observation dates.
- If PLTR falls >40% at maturity and the note hasn’t been called, principal loss is one-for-one with the stock’s decline.
- Limited upside: maximum redemption is par plus due coupon; investors do not participate in stock gains above par.
- Market value likely to be below issue price; liquidity limited; pricing sensitive to GS credit spreads, PLTR volatility and interest rates.
- Product complexity, dilution events, market disruption adjustments and discretionary determinations by GS & Co. add additional risks.
The prospectus supplement also details anti-dilution adjustments, default provisions, tax characterization (income-bearing prepaid derivative contract) and extensive hypothetical scenarios illustrating coupon and principal outcomes.
Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., is offering Autocallable Barrier Securities maturing 6 July 2027 with a total face amount of $922,000 (1,000-denomination). The unsecured notes are linked to the worst performer of three U.S. equity indices: Nasdaq-100 (22,679.01), Russell 2000 (2,175.035) and S&P 500 (6,204.95).
Key mechanics: 1) Automatic early redemption on 30 Jun 2026 if every index closes at or above its initial level, paying principal plus a 12 % premium ($1,120). 2) If not called, final payout on 30 Jun 2027 depends solely on the worst performer: • Appreciation participates at a 300 % upside rate. • If the worst performer is ≤ initial but ≥ 70 % barrier, only principal is returned. • If it falls below the 70 % barrier, investors lose 1 % of principal for each 1 % decline, up to total loss.
The notes do not pay coupons, are not listed, and carry the credit risk of both CGMHI and Citi. Issue price is $1,000, but the internal estimated value is $980.60; underwriting fee up to $10 per note. CGMI will make a secondary market on a best-efforts basis only.
Risk highlights include potential total loss of investment, reliance on a single worst-performing index, high valuation sensitivity on only two observation dates, liquidity constraints, small-cap volatility in Russell 2000, and uncertain tax treatment. The modest offering size and routine structure suggest limited impact on Citi’s overall financials.
Zscaler, Inc. (ZS) has filed a Form 144 indicating a proposed insider sale of common stock. The filing covers the potential sale of 56,428 shares with an aggregate market value of approximately $17.45 million. The shares are expected to be sold on or about 07/02/2025 through Morgan Stanley Smith Barney LLC on the NASDAQ exchange. As disclosed, Zscaler has 155,695,672 shares outstanding; therefore, the planned sale represents roughly 0.036 % of total shares.
The seller, Remo E. Canessa, previously sold 3,684 shares on 06/17/2025 for gross proceeds of $1.12 million. The current Form 144 aggregates shares acquired via restricted stock awards, performance shares, and an employee stock-purchase plan between 2018-2022. No gifts were involved and prior purchases were made either without cash consideration (share grants) or with cash (ESPP shares).
Form 144 is a notice of intent; it does not guarantee that the sale will occur, but it signals insider intent and allows the market to anticipate potential share supply. The filer attests that no material non-public adverse information is known and acknowledges Rule 144 and 10b5-1 representations.
BJ’s Wholesale Club Holdings, Inc. (BJ) — Form 4 insider transaction
President & CEO Robert W. Eddy filed a Form 4 for trades executed on 1 July 2025. Mr. Eddy, who is also a director, sold a total of 17,900 BJ common shares in three market transactions:
- 7,308 shares at a weighted-average $106.73
- 9,894 shares at a weighted-average $107.27
- 698 shares at a weighted-average $108.03
The weighted-average sale price range spanned $105.98–$108.07. After the sales, the CEO retains 368,333 shares held directly and 2,000 shares held indirectly through dependent children, leaving him with roughly 370k shares in total. The disposition represents ≈4.6 % of his prior direct ownership.
No derivative securities were reported. The filing does not reference a Rule 10b5-1 trading plan, so the sales appear discretionary. Investors often watch C-suite sales for sentiment signals; however, the executive continues to hold a sizeable equity stake, which may temper negative interpretations.